Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study

Urology. 2008 Nov;72(5):1090-5. doi: 10.1016/j.urology.2008.06.059. Epub 2008 Sep 16.

Abstract

Objectives: We examined the population-based rates of cancer-specific survival in patients with metastatic renal cell carcinoma (MRCC) treated with either partial (PN) or radical cytoreductive nephrectomy (RN).

Methods: Patients diagnosed with MRCC and treated with either PN or RN were identified within nine SEER cancer registries. Matched and unmatched Kaplan-Meier survival analyses, as well as multivariable Cox regression models compared the effect of RN (n = 1997, 97.8%) vs. PN (n = 46, 2.2%) on cancer-specific survival (CSS). Covariates consisted of age, gender, community type (rural vs urban), race, Surveillance, Epidemiology, and End Results (SEER) registry, tumor size and year of diagnosis.

Results: In multivariable unmatched Cox regression analyses, no statistically significantly difference was found in CSS between the two groups (hazard ratio [HR] 1.40, P = .16). Similarly, no difference in CSS was found in the matched analyses (HR 1.35, log rank P = .34).

Conclusion: Cytoreductive PN does not appear to undermine survival in patients with MRCC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Carcinoma, Renal Cell / mortality
  • Carcinoma, Renal Cell / secondary*
  • Carcinoma, Renal Cell / surgery*
  • Cohort Studies
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Kidney Neoplasms / mortality
  • Kidney Neoplasms / pathology*
  • Kidney Neoplasms / surgery*
  • Male
  • Middle Aged
  • Nephrectomy / methods*
  • Nephrectomy / statistics & numerical data
  • Retrospective Studies
  • SEER Program*
  • Survival Rate
  • Treatment Outcome
  • United States / epidemiology